Table 2.
Summary of Studies Reporting Survival Comparing Desmoplastic Groups
| Trial [reference] | Number of patients | Observation time (years) | Event-free survival | Overall survival | Initial treatment | ||||
|---|---|---|---|---|---|---|---|---|---|
| DMB | Non-DMB | DMB | Non-DMB | CSI | HDC ASCR | HDMTX | |||
| 1. HIT-SKK"92 [5] | 43 | 5 | 85% | 34% | 95% | 41% | NO | NO | YES |
| 2. HIT-SKK"87 [9] | 29 | 10 | 89% | 30% | 89% | 40% | YES | NO | YES |
| 3. UKCCSG/SIOP CNS9204 [8] | 31 | 5 | 35%* | 33%* | 53% | 33% | NO | NO | YES |
| 4. meta-analysis [15] | 270 | 8 | 55% | 27% | 77% | 42% | YES^ | YES^ | YES^ |
| 5. CCG-9921, this analysis | 76 | 5 | 77% | 17% | 85% | 29% | NO | NO | NO |
DMB Desmoplastic Medulloblastoma, including desmoplastic nodular medulloblastoma and medulloblastoma with extensive nodularity; CSI Craniospinal irradiation; HDC ASCR High-dose chemotherapy with autologous stem cell rescue; HDMTX High-dose methotrexate.
*
All differences in survival are statistically significant except for reference #3 event-free survival.
^
Patient cohorts in meta-analysis treated on six different regimens, including reverences 1–3 above in addition to Italian and Head-Start regimens which used HDC ASCR.